Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleBronchodilator effect of delta1-tetrahydrocannabinol administered by aerosol of asthmatic patients.
Author(s)Williams SJ, Hartley JP, Graham JD
Journal, Volume, IssueThorax 1976;31(6):720-723
Major outcome(s)significant broncholdilation with THC; faster action of salbutamol but both drugs equivalent at 1 hour
IndicationAsthmaAbstract
MedicationDelta-9-THC

Ten volunteer inpatient asthmatics in a steady state were given a single inhalation of an aerosol (63 mul) delivered in random order, on each of three consecutive days, in the laboratory of a respiratory unit. Before, and for one hour after treatment the pulse, blood pressure (lying and standing), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak flow rate (PFR), and self- rating mood scales (SRMS) were recorded. Treatments were placebo- ethanol only; delta1-tetrahydrocannabinol (THC) 200 mug in ethanol; or salbutamol 100 mug (Ventolin inhaler), administered double blind. Salbutamol and THC significantly improved ventilatory function. Maximal bronchodilatation was achieved more rapidly with salbutamol, but at 1 hour both drugs were equally effective. No cardiovascular or mood disturbance was detected, and plasma total cannabinoids at 15 minutes were undectable by radioimmunoassay. The mode of action of THC differs from that of sympathomimetic drugs, and it or a derivative may make a suitable adjuvant in the treatment of selected asthmatics.
Ten volunteer inpatient asthmatics in a steady state were given a single inhalation of an aerosol (63 mul) delivered in random order, on each of three consecutive days, in the laboratory of a respiratory unit. Before, and for one hour after treatment the pulse, blood pressure (lying and standing), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), peak flow rate (PFR), and self- rating mood scales (SRMS) were recorded. Treatments were placebo- ethanol only; delta1-tetrahydrocannabinol (THC) 200 mug in ethanol; or salbutamol 100 mug (Ventolin inhaler), administered double blind. Salbutamol and THC significantly improved ventilatory function. Maximal bronchodilatation was achieved more rapidly with salbutamol, but at 1 hour both drugs were equally effective. No cardiovascular or mood disturbance was detected, and plasma total cannabinoids at 15 minutes were undectable by radioimmunoassay. The mode of action of THC differs from that of sympathomimetic drugs, and it or a derivative may make a suitable adjuvant in the treatment of selected asthmatics.

Route(s)Inhalation
Dose(s)200 micrograms in ethanol as aerosol
Duration (days)1
Participants10 astmatic subjects
DesignControlled study
Type of publication
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]


up